Abemaciclib + Fulvestrant + Placebo
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Neoplasms
Conditions
Breast Neoplasms
Trial Timeline
Jul 22, 2014 → Dec 1, 2027
NCT ID
NCT02107703About Abemaciclib + Fulvestrant + Placebo
Abemaciclib + Fulvestrant + Placebo is a phase 3 stage product being developed by Eli Lilly for Breast Neoplasms. The current trial status is active. This product is registered under clinical trial identifier NCT02107703. Target conditions include Breast Neoplasms.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05169567 | Phase 3 | Active |
| NCT02107703 | Phase 3 | Active |
Competing Products
20 competing products in Breast Neoplasms